ResearcherHiroshima UniversityActive in the last 2 years
Masaru Furukawa
Matched on ORCID iD 0009-0002-0041-3596; OpenAlex author ID A5109260037. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20710-4↗
- Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/jcm12196245↗
- Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.02.001↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kenichiro Uemura · 3 shared papers, 2022–2026 · strength 0.53
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Bo… DOI 10.3390/jcm12196245↗
- Paper Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis o… DOI 10.1016/j.pan.2022.02.001↗
- Yasutaka Ishii · 3 shared papers, 2022–2026 · strength 0.53
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Bo… DOI 10.3390/jcm12196245↗
- Paper Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis o… DOI 10.1016/j.pan.2022.02.001↗
- Juri Ikemoto · 3 shared papers, 2022–2026 · strength 0.53
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Bo… DOI 10.3390/jcm12196245↗
- Paper Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis o… DOI 10.1016/j.pan.2022.02.001↗
- Shiro Oka · 2 shared papers, 2023–2026 · strength 0.41
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Bo… DOI 10.3390/jcm12196245↗
- Shinya Nakamura · 2 shared papers, 2022–2023 · strength 0.27
- Paper Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Bo… DOI 10.3390/jcm12196245↗
- Paper Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis o… DOI 10.1016/j.pan.2022.02.001↗
- Tomofumi Tsuboi · 2 shared papers, 2022–2023 · strength 0.27
- Paper Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Bo… DOI 10.3390/jcm12196245↗
- Paper Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis o… DOI 10.1016/j.pan.2022.02.001↗
- Takumi Harada · 1 shared paper, 2026 · strength 0.26
- Shinya Takahashi · 1 shared paper, 2026 · strength 0.26
- Yoshiaki Murakami · 1 shared paper, 2026 · strength 0.26
- Tatsuaki Sumiyoshi · 1 shared paper, 2026 · strength 0.26
- Kenjiro Okada · 1 shared paper, 2026 · strength 0.26
- Sho Tazuma · 1 shared paper, 2026 · strength 0.26
- Ryuta Shintakuya · 1 shared paper, 2026 · strength 0.26
- Ryota Kawamura · 1 shared paper, 2022 · strength 0.12
- Hiroshi Aikata · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.